Literature DB >> 29768143

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

Mrinal M Gounder1, David B Solit1, William D Tap1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29768143      PMCID： PMC6062005          DOI： 10.1056/NEJMc1511490

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Authors:  Mrinal Gounder; Ved Desai; Deborah Kuk; Narasimhan Agaram; Maria Arcila; Benjamin Durham; Mary L Keohan; Mark A Dickson; Sandra P D'Angelo; Neerav Shukla; Craig Moskowitz; Ariela Noy; Robert G Maki; Diego Adrianzen Herrera; Armando Sanchez; Anita Krishnan; Andrew Pourmoussa; Li-Xuan Qin; William D Tap
Journal:  Eur J Cancer       Date:  2015-08-19       Impact factor: 9.162

2.  Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Martin Durkin; Ronald S Go; Gaurav Goyal
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

3.  MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Authors:  Maria E Arcila; Alexander Drilon; Brooke E Sylvester; Christine M Lovly; Laetitia Borsu; Boris Reva; Mark G Kris; David B Solit; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2014-10-28       Impact factor: 12.531

4.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

5.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397
  5 in total
  12 in total

1.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

2.  Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Authors:  Jennifer A Lenz; Charles-Antoine Assenmacher; Victoria Costa; Katie Louka; Suzanne Rau; Nicholas S Keuler; Paul J Zhang; Robert G Maki; Amy C Durham; Enrico Radaelli; Matthew J Atherton
Journal:  Cancer Immunol Immunother       Date:  2021-08-20       Impact factor: 6.968

3.  Primary splenic histiocytic sarcoma successfully treated with splenectomy: a case report and literature review.

Authors:  Masayuki Kobayashi; Keita Sugawara; Ken Suzaki; Nobuharu Kosugi
Journal:  Int Cancer Conf J       Date:  2022-04-16

4.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

5.  A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors.

Authors:  Chongkai Wang; Jaideep Sandhu; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2019-12

6.  A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.

Authors:  Tadashi Kumamoto; Yuki Aoki; Tomoko Sonoda; Miho Yamanishi; Ayumu Arakawa; Masanaka Sugiyama; Nami Shirakawa; Sae Ishimaru; Yoshimasa Saito; Akiko Maeshima; Miho Maeda; Chitose Ogawa
Journal:  Int J Hematol       Date:  2018-10-25       Impact factor: 2.490

Review 7.  Histiocytosis.

Authors:  Jean-François Emile; Fleur Cohen-Aubart; Matthew Collin; Sylvie Fraitag; Ahmed Idbaih; Omar Abdel-Wahab; Barrett J Rollins; Jean Donadieu; Julien Haroche
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

8.  Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Gary A Ulaner; Esther Drill; Justin Buthorn; Michelle Ki; Lillian Bitner; Hana Cho; Robert J Young; Jasmine H Francis; Raajit Rampal; Mario Lacouture; Lynn A Brody; Neval Ozkaya; Ahmet Dogan; Neal Rosen; Alexia Iasonos; Omar Abdel-Wahab; David M Hyman
Journal:  Nature       Date:  2019-03-13       Impact factor: 49.962

9.  Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma.

Authors:  Stephanie L Skala; Jing C Ye; Jennifer Stumph; William R Macon; Frances R Quinones; Vadim Khachaturov; Rhett P Ketterling; Rajan Dewar
Journal:  Clin Pathol       Date:  2019-09-29

10.  The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.

Authors:  Caoimhe Egan; Justin Lack; Shannon Skarshaug; Thu Anh Pham; Zied Abdullaev; Liqiang Xi; Svetlana Pack; Stefania Pittaluga; Elaine S Jaffe; Mark Raffeld
Journal:  Mod Pathol       Date:  2020-09-14       Impact factor: 8.209
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.